CEO Albert Bourla said on Monday that the drugmaker could move some of its overseas manufacturing to its U.S. plants if necessary, as the Trump administration considers imposing tariffs on pharmaceuticals.

As biopharma players continue to parse out what the second Trump administration means for the industry, Pfizer CEO Albert Bourla, Ph.D., outlined one potential response by his company if pharmaceut | Pfizer’s local manufacturing setup is already well positioned in the U.

Eli Lilly also responded to the President's tariff warnings by investing $27 billion to construct four manufacturing facilities across the U.S. in five years.

Pfizer CEO Albert Bourla said on Monday the drugmaker might move overseas manufacturing to its existing plants in the United States, if required, as the Trump administration threatens numerous tariffs on imported goods.

Pfizer CEO Albert Bourla announced the possibility of shifting overseas manufacturing to U.S. plants. This response is due to the Trump administration's tariff threats on imported goods. Bourla mentioned their U.

Pfizer CEO Albert Bourla said on Monday the drugmaker might move overseas manufacturing to its existing plants

Pfizer CEO Albert Bourla on Monday said that the company might move overseas manufacturing to its existing plants in the United States. The plan comes as the Trump administration